Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for alprazolam
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alprazolam or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on alprazolam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Alprazolam Top results for alprazolam - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alprazolam The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory
Alprazolam-induced dose-dependent anorgasmia: case analysis 30083378 2018 11 14 2056-4724 4 4 2018 Jul BJPsych open BJPsych Open Alprazolam-induced dose-dependent anorgasmia: case analysis. 274-277 10.1192/bjo.2018.35 Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer (...) these symptoms and clinicians do not pose directed questions to determine their presence or severity. This issue is especially important in psychiatric patients, for whom most common psychotropics may cause sexual dysfunctions (antidepressants, antipsychotics, anxiolytics and mood-stabilising agents). There is limited literature addressing benzodiazepines, and alprazolam in particular. To report dose-dependent alprazolam anorgasmia. Case analysis with PubMed literature review. A 30-year-old male psychiatric
Alprazolam for essential tremor. BACKGROUND: Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit (...) . Alprazolam has been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain. OBJECTIVES: PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET. SEARCH METHODS: We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register
Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect Srisurapanont M, Boonyanaruthee V Authors' objectives To compare the effectiveness of alprazolam and standard antidepressants in the treatment (...) of depression. Searching MEDLINE was searched up to June 1995 using the following headings and terms: 'depressive disorder-drug therapy', 'alprazolam', 'antidepressants' and 'randomised-controlled trial'. Cross-referencing was used to seek out further studies. Study selection Study designs of evaluations included in the review Double-blind, randomised controlled trials (RCTs), which compared the antidepressant effect of alprazolam to that of a standard antidepressant, were included if they measured
A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. 7791258 1995 07 25 1995 07 25 2016 10 17 0098-7484 274 1 1995 Jul 05 JAMA JAMA A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. 51-7 To determine the effectiveness of oral micronized progesterone, alprazolam, and placebo in premenstrual syndrome (PMS) treatment and the effect of clinical contact on treatment responses (...) protocol in which 300 mg of oral micronized progesterone, 0.25 mg of alprazolam, or placebo was administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle, including taper. The mean daily dose at the third treatment was 1760 mg of progesterone or 1.5 mg of alprazolam. Subjects were randomized to brief (< 20 minutes) or extended (50 minutes) visits. Daily symptom report (DSR) scored for total DSR symptoms, four DSR factors. Alprazolam was significantly better than
Comparison of alprazolam, imipramine, and placebo in the treatment of depression. 6133970 1983 07 08 1983 07 08 2016 10 17 0098-7484 249 22 1983 Jun 10 JAMA JAMA Comparison of alprazolam, imipramine, and placebo in the treatment of depression. 3057-64 Alprazolam is the first of the triazolobenzodiazepines to be studied in a large population of depressed patients. In a six-week, double-blind multicenter comparison of alprazolam, imipramine hydrochloride, and placebo in the treatment of 723 (...) patients with depression, the two active drugs were statistically more effective than placebo. Alprazolam was at least as effective as imipramine in relieving depressive symptoms, significantly more effective in relieving somatic symptoms, and showed an earlier onset of activity in some measurements. Anticholinergic side effects were reported most often by patients receiving imipramine, while drowsiness was the only side effect reported most often in the alprazolam group. The Feighner Diagnostic